‘Shrooms for the Blues: Psilocybin to alleviate difficult-to-treat depression

Summary

Psilocybin, a compound found in psychedelic mushrooms, shows promise as an antidepressant for treatment-resistant and cancer-related depression, which are difficult to treat with conventional methods. Evidence indicates that psilocybin positively affects mood through serotonin system interactions, leading to lasting improvements. Trials indicate it is safe when given in small doses in clinical settings, despite concerns over neurotoxicity or psychosis. The findings suggest significant benefits for patients who have not responded to other treatments.

Study at a glance

Abstract

Depression is a devastating disease, affecting hundreds of millions of people worldwide. Cases of difficult-to-treat depression are also increasingly common, exposing the ineffectiveness of currently available treatments. This paper reviews evidence supporting the use of psilocybin, the prodrug found in psychedelic mushrooms, as a potential antidepressant for treatment-resistant and cancer-related depression, two prevalent kinds of difficult-to-treat depression. Through its interactions with the serotonin system, psilocybin appears to create positive and enduring effects on mood that are fundamentally different from conventional antidepressants. Despite concerns about psilocybin’s potential to cause neurotoxicity or psychosis, trials have shown this drug to be quite safe, especially when administered in small doses in a clinical setting. These studies suggest that, both neurologically and psychologically, psilocybin has led to previously unreachable successes for patients struggling with cancer-related and treatment-resistant depression.